IV Ketorolac on Platelet Function Post-Cesarean Delivery (KetoPltAgg)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03805607

Recruitment Status : Recruiting

First Posted : January 15, 2019

Last Update Posted : August 18, 2021

See Contacts and Locations

Sponsor:

Collaborator:

Society for Obstetric Anesthesia and Perinatology

Information provided by (Responsible Party):

John J. Kowalczyk, Beth Israel Deaconess Medical Center

Study Description

Brief Summary:

Cesarean delivery has become the most common surgical procedure in the US. Non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to improve the quality of post-cesarean analgesia and markedly reduce opioid consumption. The effect of NSAIDs on healthy volunteers results in inhibition of platelet aggregation and prolonged bleeding time. However, in the obstetric population, the presence and degree of platelet inhibition after NSAID exposure is less clear. The investigators plan to use Platelet Aggregometry and Thromboelastography (TEG) to evaluate the effect of ketorolac on platelets.

Condition or disease	Intervention/treatment	Phase
Cesarean Section Complications Postoperative Pain Coagulation Defect; Postpartum Nonsteroidals (NSAIDs)Toxicity Postpartum Hemorrhage	Drug: Ketorolac Tromethamine 30 MG/ML Drug: Placebos	Phase 4

Show detailed description

Detailed Description:

Cesarean delivery has become the most common surgical procedure in the US, with over 1.2 million cesarean deliveries performed each year. The addition of non-steroidal anti-inflammatory drugs (NSAIDs) to a post-cesarean analgesic regimen has been shown to improve the quality of post-cesarean analgesia and markedly reduce opioid consumption. As a result, fewer patients incur opioid related side-effects such as nausea and vomiting, respiratory compromise, sedation, and impaired breast-feeding.

The effect of NSAIDs on healthy volunteers is relatively well-described. Most commonly, NSAIDs inhibit membrane-bound cyclooxygenase 1 (COX-1), the enzyme responsible for the production of the platelet agonist thromboxane A2. This ultimately results in inhibition of platelet aggregation and prolonged bleeding time. However, in the obstetric population, the presence and degree of platelet inhibition after NSAID exposure is less clear. This has limited the incorporation of NSAIDs into protocols for postpartum analgesia following cesarean delivery.

Platelet Function Assessment 100 (PFA) assays, with collagen/epinephrine and collagen/ADP (adenosine diphosphate) as agonists, can reliably test for platelet inhibition. PFA has been utilized to examine the anti-platelet effects of platelet inhibitors including NSAIDs in studies involving non-obstetric patients. Similarly, platelet aggregometry has been used to evaluate the platelet inhibitory effects of NSAIDs. Thromboelastography (TEG) has been shown in numerous studies to represent in-vivo clot strength and function.

Research in this field is needed as physiologic changes of pregnancy combined with significant surgical blood loss and hemodilution at cesarean delivery may alter the effect on maternal platelet function. This has become more pressing as postpartum thromboprophylaxis is likely to be more commonly considered for patients after cesarean delivery. In their most recent unofficial guidelines, the American Society of Regional Anesthesia state that NSAIDs should not be used with thromboprophylaxis after patients received neuraxial blockade (ASRA App). However, to the best of our knowledge, there is limited data, only utilizing bleeding time,5 examining the potential platelet inhibitory effect of NSAIDs in a low-risk healthy cohort undergoing cesarean delivery.

Protocol:

Brief Study Protocol After obtaining Institutional Review Board (IRB) approval, patients will be randomly assigned to receive either IV ketorolac 30 mg (n=15) or normal saline (n=15) based on a pre-assigned randomization sequence. The assignment for each patient will be kept in sealed opaque envelopes. After obtaining written informed consent, an anesthesiologist not involved in the study will open the envelope and will prepare the study drug. The patient and the study investigators will be blinded to the study drug.

Baseline platelet count, coagulation parameters (activated partial thromboplastin time (APTT), prothrombin time (PT), Fibrinogen) and TEG parameters will be measured pre-operatively on the day of surgery. Routine lab work obtained at this time will require 10 ml of blood, while study related tests will require 5.4 ml. Each patient will undergo either spinal or combined spinal epidural anesthesia with our standard cesarean induction dose of hyperbaric intrathecal 0.75% bupivacaine 1.5 ml, intrathecal fentanyl 25 micrograms and intrathecal morphine 250 micrograms. The patient will be moved to the supine position with left lateral uterine displacement. When a T6 sensory level to pinprick is achieved, cesarean delivery will be allowed to proceed. At the completion of the surgery, Platelet Aggregometry and TEG parameters will be performed to assess for intraoperative changes to TEG and establish baseline Platelet Aggregometry values. A total volume of 18.9 ml of blood will be withdrawn for the study at this time. While under the effect of the spinal medication, meaning that the patient is unable to fill sharp in their feet, the patient may elect to have this blood and the subsequent blood drawn from their foot to avoid unnecessary pain. These blood draws would only be performed by an anesthesiologist and only if a suitable site was identified. Performing venipucture for lab draws in the feet is not known to increase the risk of complications from blood draws when compared to the upper extremity. The study drug will be administered upon completion of the case. Platelet Aggregometry and TEG parameters will be performed 10 min after study drug administration. An additional volume of 18.9 ml of blood will be withdrawn for the study at this time. After blood samples have been obtained, patients in each group will receive the alternate therapy (ie placebo group receives ketorolac and ketorolac receives placebo), allowing both groups to benefit from the analgesic effect of ketorolac. Supplemental analgesia will be administered according to a standard post-operative pain management protocol on labor and delivery.

Statistical analysis: Data will be assessed for normality using normality plots and the Kolmogorov-Smirnov test. Demographic, obstetric, and perioperative data will be presented as mean (SD) or median [interquartile range]. Between-group comparisons will be assessed using the unpaired t test and Mann-Whitney U test, where appropriate. Within-group before vs. after NSAID exposure changes will be assessed using the paired t test and Wilcoxon signed rank test, where appropriate. The percentage change from baseline for each PFA, TEG, and lab parameter will also be calculated.

Sample size justification: There is limited data on the affect of ketorolac on quantitative coagulation studies, particularly in the obstetric population. Based on available data from a prior study examining platelet inhibition of non-opioid analgesics, a PFA closure time ≥173 seconds can be used to classify platelet inhibition. Using the aforementioned data on epinephrine-induced PFA closure time, the investigators estimate that, before and after ketorolac exposure, 25% and 70% patients respectively would exhibit prolonged PFA closure times. With an alpha error of 0.05 and a beta error of 0.8, the investigators estimated that a sample size of 18 patients per group would provide 80% power. Additional studies have examined the affect of ketorolac on platelet aggregometry. Platelet aggregometry to collagen was diminished in the ketorolac group from preoperative to poststudy drug data points (90.8% +/- 7.6% to 60.5% +/- 32.5%; P < 0.01). With an alpha error of 0.05 and a beta error of 0.8, the investigators estimated that a sample size of 19 patients per group would provide 80% power.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	40 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Intervention Model Description:	Randomized Double-blind Placebo Controlled Study
Masking:	Triple (Participant, Care Provider, Investigator)
Masking Description:	Placebo (normal saline) or ketorolac in syringe prepared by the investigational pharmacy with study patient number and blinding key maintained by investigational pharmacy until time of unblinding.
Primary Purpose:	Diagnostic
Official Title:	Prospective Evaluation of the Effects of IV Ketorolac on Platelet Function Post-Cesarean Delivery
Actual Study Start Date :	January 18, 2021
Estimated Primary Completion Date :	October 2021
Estimated Study Completion Date :	January 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cesarean Section

Drug Information available for: Tromethamine Ketorolac Ketorolac tromethamine

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Placebo Comparator: Placebo 1 ml of normal saline	Drug: Placebos Normal Saline Other Names: Placebo Normal Saline
Experimental: Ketorolac 30 mg of ketorolac in 1 ml	Drug: Ketorolac Tromethamine 30 MG/ML Ketorolac 30 mg Other Names: ketorolac Ketorolac Tromethamine Ketorolac Injectable Solution

Outcome Measures

Primary Outcome Measures :

Platelet Aggregometry Percent Light Transmission [ Time Frame: 15 minutes after dosing of placebo or ketorolac ]
Platelet Aggregometry uses measurements platelet rich blood or serum samples and activating agents to analyze the percent change in light transmission as a marker of platelet aggregation.

Secondary Outcome Measures :

Thromboelastogram parameters including Reaction time (R) [ Time Frame: 15 minutes after dosing of placebo or ketorolac ]
Thromboelastogram parameters including Reaction time (R)
Thromboelastogram parameters including Angle (alpha) [ Time Frame: 15 minutes after dosing of placebo or ketorolac ]
Thromboelastogram parameters including Angle (alpha)
Thromboelastogram parameters including Kinetics (K) [ Time Frame: 15 minutes after dosing of placebo or ketorolac ]
Thromboelastogram parameters including Kinetics (K)
Thromboelastogram parameters including Maximum Amplitude (MA) [ Time Frame: 15 minutes after dosing of placebo or ketorolac ]
Thromboelastogram parameters including Maximum Amplitude (MA)

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years to 45 Years (Adult)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Pregnant
Undergoing routine, scheduled cesarean section
Gestation >37 weeks
Singleton gestation
Intraoperative anesthesia - 1.5 ml of intrathecal bupivicaine 0.75%, 25mcg of intrathecal fentanyl and 250 mcg of intrathecal morphine via Spinal or Combined Spinal Epidural

Exclusion Criteria:

Pre-eclampsia with severe features or HELLP
Allergy to NSAIDs
Pre-existing bleeding disorder
Other major risk factor for postpartum hemorrhage (placenta accreta, large uterine fibroid)
Chronic kidney disease
Plt count less than 100k
Gastric ulcer or gastric bleeding
Pre-existing uterine bleeding or disseminated intravascular coagulation
Patient or Obstetrician refusal
Intraoperative exclusion criteria - Postpartum hemorrhage (EBL >1000 ml) or unplanned intraoperative extension of surgery

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03805607

Contacts

Layout table for location contacts

Contact: John J Kowalczyk, MD	617-667-3112	jkowalcz@bidmc.harvard.edu
Contact: Phil Hess, MD	617-667-3112	phess@bidmc.harvard.edu

Locations

Layout table for location information

United States, Massachusetts
Beth Israel Deaconess Medical Center	Recruiting
Boston, Massachusetts, United States, 02215
Contact: John J. Kowalczyk, MD 617-667-3112 jkowalcz@bidmc.harvard.edu

Sponsors and Collaborators

Beth Israel Deaconess Medical Center

Society for Obstetric Anesthesia and Perinatology

More Information

Layout table for additonal information

Responsible Party:	John J. Kowalczyk, Instructor in Anaesthesia, Beth Israel Deaconess Medical Center
ClinicalTrials.gov Identifier:	NCT03805607
Other Study ID Numbers:	2018P000625
First Posted:	January 15, 2019 Key Record Dates
Last Update Posted:	August 18, 2021
Last Verified:	August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No
Plan Description:	Individual participant data (IPD) will not be shared.

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	Yes
Studies a U.S. FDA-regulated Device Product:	No
Product Manufactured in and Exported from the U.S.:	Yes

Keywords provided by John J. Kowalczyk, Beth Israel Deaconess Medical Center:


Cesarean Section Complications Postoperative Pain Coagulation Defect; Postpartum Nonsteroidals (NSAIDs)Toxicity	Postpartum Hemorrhage Ketorolac Cesarean Delivery Platelet Function

Additional relevant MeSH terms:

Layout table for MeSH terms

Postpartum Hemorrhage Hemostatic Disorders Blood Coagulation Disorders Hemorrhage Pain, Postoperative Pathologic Processes Postoperative Complications Pain Neurologic Manifestations Obstetric Labor Complications Pregnancy Complications Puerperal Disorders Uterine Hemorrhage Hematologic Diseases Vascular Diseases	Cardiovascular Diseases Hemorrhagic Disorders Ketorolac Ketorolac Tromethamine Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Cyclooxygenase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action

To Top